COMPARATIVE EVALUATION OF THE SINGLE AND COMBINED EFFECTS OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS
Keywords:
type 2 diabetes mellitus, GLP-1 receptor agonists, SGLT2 inhibitors, semaglutide, liraglutide, dapagliflozin, empagliflozin, combination therapy, glycemic control, body weight, cardiorenal protection.Abstract
Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance, impaired β-cell function, excess body weight, and the development of cardiovascular and renal complications. In recent years, pharmacotherapeutic approaches aimed not only at improving glycemic control but also at reducing cardiorenal and metabolic risks have been increasingly developed. GLP-1 receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors play an important role in this therapeutic approach. This article provides a comparative analysis of the effects of GLP-1 receptor agonists and SGLT2 inhibitors used as monotherapies and in combination on glycemic control, body weight, arterial blood pressure, lipid metabolism, and renal function. GLP-1 receptor agonists primarily improve glycemic control by enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, and slowing gastric emptying, while also contributing to body weight reduction. SGLT2 inhibitors, in contrast, reduce renal glucose reabsorption and exert their effects through insulin-independent glycosuria, while providing important cardiorenal protective benefits. Because these two pharmacological classes have distinct and complementary mechanisms of action, their combination represents a promising therapeutic approach for achieving comprehensive metabolic control.
References
1.Davies M.J., Aroda V.R., Collins B.S., et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034.
2. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S158–S178.
2.Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720.
4. Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375:311–322. doi:10.1056/NEJMoa1603827.
3.5. Marso S.P., Bain S.C., Consoli A., et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375:1834–1844. doi:10.1056/NEJMoa1607141.
4.6. Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R., et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2020;383:1436–1446. doi:10.1056/NEJMoa2024816.
7. Zelniker T.A., Wiviott S.D., Raz I., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. 2019;393(10166):31–39. doi:10.1016/S0140-6736(18)32590-X.
5.8. Sattar N., Lee M.M.Y., Kristensen S.L., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The Lancet Diabetes & Endocrinology. 2021;9(10):653–662.
9. Frias J.P., Guja C., Hardy E., et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy. The Lancet Diabetes & Endocrinology. 2016;4(12):1004–1016.
6.10. Frías J.P., Davies M.J., Rosenstock J., et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385:503–515.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal